Patents Assigned to BEBETTER MED INC.
  • Publication number: 20250034116
    Abstract: The present invention disclosed a 1,4-diheterocyclic substituted aromatic ring or aromatic heterocyclic compound represented by formula (I). The compound can effectively inhibit the generation of 20-HETE, and has high activity, high selectivity and good pharmacokinetic characteristics. By means of the inhibition on the generation of 20-HETE, the compound can be used for treating various diseases related to 20-HETE, and thus has a great application value.
    Type: Application
    Filed: September 26, 2024
    Publication date: January 30, 2025
    Applicant: BeBetter Med Inc.
    Inventors: Xiong CAI, Yuanhui QING, Qijie HE, Yiting LIU, Shaobin WU, Yaonan HE, Huichen TAN, Yunwo WENG, Bin LIU, Mingsheng LIN, Xinlan DENG, Junling ZHU, Qiao FENG, Changgeng QIAN
  • Publication number: 20220389013
    Abstract: The present disclosure provides the Pyridopyrimidinone compounds having the structure represented by the general Formula (II) and applications thereof. Studies have shown that the compounds provided by the present disclosure can effectively inhibit the KRAS G12C mutation. KRAS mutation accounts for a large proportion of tumors, and currently there is no approved drug for its treatment. The compounds provided by the present disclosure have the potential to become a therapeutic medicine for malignant tumors (especially non-small cell lung cancer (NSCLC) and colorectal cancer) haboring KRAS G12C mutation, and have great application value.
    Type: Application
    Filed: July 20, 2022
    Publication date: December 8, 2022
    Applicant: BeBetter Med Inc.
    Inventors: Xiong CAI, Yunwo WENG, Yuanhui QING, Mingsheng LIN, Bin LIU, Qijie HE, Yiting LIU, Qiao FENG, Fushun FAN, Changgeng QIAN
  • Patent number: 11306102
    Abstract: Provided are a 1,3-di-substituted ketene compound having a structure as represented by formula (I) and an application thereof. Such a type of compound primarily activates peroxisome proliferator-activated receptor (PPAR) ?, and also activates PPPA? and PPPA?. The compound may be used to treat various diseases associated with PPAR regulation and control abnormality, such as non-alcoholic fatty liver disease, and especially in treating non-alcoholic hepatitis, and may potentially be used in the treatment of diseases comprising diabetes, obesity, fibrotic diseases, cardiovascular diseases (comprising heart failure, atherosclerosis, and so on), kidney diseases (comprising chronic kidney disease, renal failure, and so on), and brain degenerative diseases (comprising Alzheimer's disease and so on), having great application value.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: April 19, 2022
    Assignee: BEBETTER MED INC.
    Inventors: Xiong Cai, Changgeng Qian, Chunqiang Ye, Qijie He
  • Patent number: 11267802
    Abstract: Provided are a 2, 4-di-(nitrogen containing group) substituted pyrimidine compound represented by a general formula (I), a pharmaceutically acceptable salt and a stereoisomer thereof, a preparation method thereof, and a use thereof in preparation of anti-tumor drugs. The compound having a structural feature shown in the general formula (I) can selectively suppress activity of mutant epidermal growth factor receptors (EGFR), including single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. The compound has a weak suppression effect on wild-type EFGR and a very high selectivity, and thus it has a potential to be used in preparation of drugs for treating EGFR mutant tumors, especially non-small cell lung cancer (NSCLC) comprising a T790M EGFR mutation.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: March 8, 2022
    Assignee: BEBETTER MED INC.
    Inventors: Xiong Cai, Changgeng Qian, Yunwo Weng, Bin Liu, Yanyan Wang, Mingsheng Lin, Junqi Li, Yuanhui Qing, Huajin You, Shiqing Zhou, Weicai Xue